R1 Therapeutics announces commencement of global Phase 2b trial of AP306 for hyperphosphatemia in patients on dialysis
AP306 is a first-in-class pan phosphate transporter inhibitor in development as a monotherapy for hyperphosphatemia, a near-universal and serious complication in chronic kidney disease patients Study underway with first patient randomized in the global Phase 2b trial of AP306 conducted in partnership with Alebund in the US and China Study builds on positive Phase 2a […]



